Terms: = Pancreatic cancer AND FLI1, SIC-1, 2313, ENSG00000151702, Q01543, EWSR2 AND Treatment
4 results:
1. Predictors and benefits of multiagent chemotherapy for pancreatic adenocarcinoma: Timing matters.
Valdera FA; O'Shea AE; Smolinsky TR; Carpenter EL; Adams AA; McCarthy PM; Tiwari A; Chick RC; Kemp-Bohan PM; Van Decar S; Thomas KK; Bader JO; Peoples GE; Clifton GT; Stojadinovic A; Nelson DW; Vreeland TJ
J Surg Oncol; 2024 Feb; 129(2):244-253. PubMed ID: 37800378
[TBL] [Abstract] [Full Text] [Related]
2. Hsa_circ_0007401 regulates gemcitabine resistance of pancreatic cancer through the hsa-miR-6509-3p/fli1 axis.
Han C; Zheng H; Hu D; Wang M; Wang H; Zhang L
Medicine (Baltimore); 2023 May; 102(21):e33775. PubMed ID: 37233428
[TBL] [Abstract] [Full Text] [Related]
3. GSK2126458 has the potential to inhibit the proliferation of pancreatic cancer uncovered by bioinformatics analysis and pharmacological experiments.
Feng Y; Jiang Y; Hao F
J Transl Med; 2021 Aug; 19(1):373. PubMed ID: 34461940
[TBL] [Abstract] [Full Text] [Related]
4. Safety, Tolerability, and Preliminary Activity of LB-100, an Inhibitor of Protein Phosphatase 2A, in Patients with Relapsed Solid Tumors: An Open-Label, Dose Escalation, First-in-Human, Phase I Trial.
Chung V; Mansfield AS; Braiteh F; Richards D; Durivage H; Ungerleider RS; Johnson F; Kovach JS
Clin Cancer Res; 2017 Jul; 23(13):3277-3284. PubMed ID: 28039265
[No Abstract] [Full Text] [Related]
